Immunotherapy has now been established as one of the cornerstones of anticancer treatments. There is tremendous potential for synergistic combinations of cancer immunotherapies and also for combining cancer immunotherapies with targeted therapies. Our preclinical pipeline consists of additional targeted therapies and immuno-oncology agents including a PD-L1 monoclonal antibody, a next generation RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and candidates from several undisclosed preclinical immuno-oncology programs. These agents could facilitate recognition and sensitivity to effector functions by cytotoxic T lymphocytes (CTL) or suppress the regulatory T cells (Treg), thereby sensitizing cancer cells to immunotherapies. To evaluate the potential different combinations, we are using our extensive collection of in vitro, in vivo and ex vivo cancer models. These proprietary models developed in house have elements of a functional immune system integrated through allogeneic, syngeneic and humanization methods, hence are more physiologically relevant. We believe we are well positioned to combine our PD-1 monoclonal antibody with other clinical-stage and preclinical candidates in our pipeline portfolio to target multiple points in the cancer immunity cycle.
As an innovative biotechnology company with research facilities in China, we have been able to attract an internationally trained research team of over 140 talented scientists. The team has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support our drug discovery effort. We believe our strong research capabilities will continue generating high quality first-in-class or best-in-class drug candidates in the future.